Adma Biologics (ADMA) FCF Margin (2011 - 2025)
Adma Biologics' (ADMA) quarterly FCF Margin came in at 24.83% in Q4 2025, down 1554.0% YoY from 1.71% in Q4 2024, and up 3200.34% on a QoQ basis from 0.8% in Q3 2025.
Adma Biologics (ADMA) FCF Margin (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of FCF Margin data on file, last reported at 24.83% in Q4 2025.
- Quarterly FCF Margin fell 1554.0% year-over-year to 24.83% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5.45% (down 2045.0% YoY) and the FY2025 annual result came in at 5.45%, down 2045.0% from the prior year.
- FCF Margin grew to 24.83% in Q4 2025, from 0.8% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 40.66% in Q2 2024 to a low of 223.07% in Q1 2021.
- A 5-year average of 32.71% and a median of 16.38% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2021 — FCF Margin surged 18912 bps — and 2025, when it tumbled 2531 bps.
- Tracing ADMA's FCF Margin over 5 years: stood at 67.53% in 2021, then jumped by 67 bps to 22.26% in 2022, then soared by 200 bps to 22.19% in 2023, then soared by 82 bps to 40.37% in 2024, then plunged by 38 bps to 24.83% in 2025.
- The last three FCF Margin figures came in at 24.83% (Q4 2025), 0.8% (Q3 2025), and 15.34% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.83% |
| Sep 30, 2025 | -0.80% |
| Jun 30, 2025 | 15.34% |
| Mar 31, 2025 | -21.23% |
| Dec 31, 2024 | 40.37% |
| Sep 30, 2024 | 20.00% |
| Jun 30, 2024 | 40.66% |
| Mar 31, 2024 | -5.58% |
| Dec 31, 2023 | 22.19% |
| Sep 30, 2023 | 10.21% |
| Jun 30, 2023 | -11.53% |
| Mar 31, 2023 | -29.29% |
| Dec 31, 2022 | -22.26% |
| Sep 30, 2022 | -40.56% |
| Jun 30, 2022 | -22.36% |
| Mar 31, 2022 | -99.15% |
| Dec 31, 2021 | -67.53% |
| Sep 30, 2021 | -78.34% |
| Jun 30, 2021 | -206.04% |
| Mar 31, 2021 | -223.07% |